Top Markets
#1 Amp Amp +51.78%
#2 Quant Quant +51.18%
#3 PulseChain PulseChain +46.65%
#4 Quack AI Quack AI +40.73%
#5 Fake World Assets Fake World Assets +30.31%
#6 Talus Network Talus Network +28.70%
#7 DoubleZero DoubleZero +22.81%
#8 Kamino Kamino +22.57%
#9 Pearl Pearl +21.62%
#10 SOON SOON +17.03%
Coin of the day
Amp Amp
सेटिंग्स
भाषा
हिन्दी
मुद्रा
USD
थीम
Decibel Therapeutics, Inc. Decibel Therapeutics, Inc.

Decibel Therapeutics, Inc.

DBTX
शेयरों में रैंक #26900
Decibel Therapeutics, Inc. (DBTX) is a clinical-stage biotechnology firm... Decibel Therapeutics, Inc. (DBTX) is a clinical-stage biotechnology firm dedicated to pioneering innovative therapies for a range of hearing and balance impairments. Their research and development efforts are concentrated across three primary therapeutic avenues: 1. Gene Therapies for Congenital, Monogenic Hearing Loss: These programs aim to re-establish functional cellular activity within the cochlea, thereby counteracting hearing deficiencies stemming from single gene mutations. 2. Gene Therapies for Hair Cell Regeneration: This pipeline focuses on replenishing lost hair cells in the inner ear to alleviate acquired hearing and balance conditions. 3. Otoprotection Therapeutic: Currently in clinical development, this therapeutic is designed to safeguard cancer patients from hearing loss induced by cisplatin chemotherapy. A flagship gene therapy candidate, DB-OTO, is being developed to restore auditory function in individuals suffering from profound hearing loss linked to mutations in the otoferlin gene. The company is also advancing several other programs, including DB-ATO and AAV.201, gene therapies intended to regenerate lost vestibular hair cells and thus re-establish balance in patients with bilateral vestibulopathy. DB-020 is undergoing Phase 1b clinical trials for the prevention of hearing loss caused by cisplatin. Further gene therapies in development include AAV.103 for individuals with a gap junction beta-2 (GJB2) deficiency, AAV.104 for those with a stereocilin (STRC) deficiency, and a cochlear hair cell regeneration program that employs AAV-based gene therapy to convert supporting cells into functional outer hair cells using cell-selective reprogramming factors. Decibel Therapeutics maintains a strategic alliance with Regeneron Pharmaceuticals, Inc., specifically for co-developing gene therapies addressing monogenic forms of inherited hearing loss. Established in 2013 and initially known as Hearing Inc., the company rebranded as Decibel Therapeutics, Inc. in April 2014. Its operations are headquartered in Boston, Massachusetts.
शेयर मूल्य
$4.91
अंतिम समन्वयन: 2023-10-04
मार्केट कैप
$36.12M
बदलाव (1 दिन)
0.00%
बदलाव (1 वर्ष)
-99.13%
देश
US
व्यापार Decibel Therapeutics, Inc. (DBTX)

श्रेणी

Healthcare
Decibel Therapeutics, Inc. (DBTX) के लिए बकाया शेयरों की संख्या
June 2026 की स्थिति में बकाया शेयरों की संख्या: 103.40M
Decibel Therapeutics, Inc. की नवीनतम वित्तीय रिपोर्ट और शेयर मूल्य के अनुसार, कंपनी के वर्तमान बकाया शेयरों की संख्या 103.40M है। December 2024 के अंत में कंपनी के पास 107.90M बकाया शेयर थे। बकाया शेयरों की संख्या आमतौर पर शेयर स्प्लिट्स और शेयर बायबैक से प्रभावित होती है।
Decibel Therapeutics, Inc. (DBTX) के लिए 2000 से 2026 तक बकाया शेयरों का इतिहास
प्रत्येक वर्ष के अंत में बकाया शेयर
वर्ष बकाया शेयर परिवर्तन
2026 (TTM) 103.40M -1.15%
2025 104.60M -3.06%
2024 107.90M 1.12%
2023 106.70M -0.37%
2022 107.10M 1.32%
2021 105.70M -1.77%
2020 107.60M -1.47%
2019 109.20M -4.88%
2018 114.80M -0.95%
2017 115.90M -0.30%
2016 116.25M 0.89%
2015 115.23M 1.60%
2014 113.41M 1.97%
2013 111.22M 0.13%
2012 111.07M 22.58%
2011 90.61M 9.27%
2010 82.93M 3.94%
2009 79.78M 1.21%
2008 78.83M 18.83%
2007 66.33M 14.43%
2006 57.97M 3.61%
2005 55.95M 0.96%
2004 55.42M 9.85%
2003 50.45M 14.79%
2002 43.95M 4.42%
2001 42.09M 19.66%
2000 35.17M 0.00%
समान कंपनियों या प्रतिस्पर्धियों के लिए बकाया शेयर
कंपनी बकाया शेयर अंतर देश
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M 145.55%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M 282.98%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -39.86%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M 363.16%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH